Metastatic UM
What do I need to know?
Treatment of Metastatic UM If UM has spread beyond the eye, it is considered metastatic . Approximately half of UM patients will develop metastatic disease, although each person’s individual risk is based on factors such as tumor genetics and other clinical characteristics. When UM metastasizes, it first spreads to the liver 85–90% of the time. It is important to note that the treatment of uveal melanoma can be very different from that of cutaneous melanoma. While some treatments are used both in cutaneous melanoma and UM, the diseases are very different. It is important for your treatment team to understand the differences. There are currently two FDA-approved treatments for metastatic uveal melanoma (UM): tebentafusp (Kimmtrak), approved in 2022 for patients who test positive for HLA-A*02:01, and melphalan/Hepatic Delivery System (HEPZATO KIT), a treatment for unresectable hepatic (liver) metastases. Clinical trials exploring additional treatment options are ongoing and remain an important consideration for many patients.
Visit melanoma.org to find an ocular melanoma treatment center and a specialist who can discuss all possible treatment options with you, including clinical trials.
MRF
12
Made with FlippingBook Ebook Creator